United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
and RESEARCH TRIANGLE PARK, N.C., June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Corporation, Nasdaq: LQDA) and a former United Therapeutics employee who later joined Liquidia as an executive.
- and RESEARCH TRIANGLE PARK, N.C., June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Corporation, Nasdaq: LQDA) and a former United Therapeutics employee who later joined Liquidia as an executive.
- The claims allege that Liquidia conspired with the former employee to misappropriate United Therapeutics' trade secrets, including regulatory submissions and detailed financial forecasts, in the development of Liquidia's product, LIQ861.
- The NDA was filed under the 505(b)(2) regulatory pathway with United Therapeutics' product, Tyvaso (treprostinil) Inhalation Solution, as the reference listed drug.
- During discovery in the patent infringement case, United Therapeutics uncovered evidence that a former United Therapeutics employee took United Therapeutics' trade secrets when he left the company and joined Liquidia to develop LIQ861.